ORYZON GENOMICS S.A.

ORY
Delayed Bolsas y Mercados Espanoles - 08:57 2022-12-07 am EST
2.080 EUR -0.24%

Turn to zoom
Prev.2.08500000
Open2.07500000
High2.10500000
Low2.07000000
Volume27 685
Latest news
11/09
11/09
11/09
11/07
Chart ORYZON GENOMICS S.A.
Technical analysis trends
Short TermMid-TermLong Term
TrendNeutralBearishBearish
Resistance2,202,432,57
Spread/Res.-5,5%-14%-19%
Spread/Supp.0,73%0,73%0,48%
Support2,072,072,07
Financials
Sales 2022 3,60 M 3,79 M 3,79 M
Net income 2022 -4,24 M -4,46 M -4,46 M
Net Debt 2022 2,27 M 2,38 M 2,38 M
P/E ratio 2022 -25,0x
Yield 2022 -
Capitalization 112 M 118 M 118 M
EV / Sales 2022 31,7x
EV / Sales 2023 34,3x
Nbr of Employees 44
Free-Float 80,9%
Company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase...
Sector :
Other Biotechnology & Medical Research
Calendar :
2022-12-12 Presentation
Trading Rating :
Investor Rating : -

Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,09 €
Average target price 8,83 €
Spread / Average Target 324%